Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjørn, M.E., de Stricker, K., Kjær, L., Ellemann, K., Hasselbalch, H.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216335/
https://www.ncbi.nlm.nih.gov/pubmed/25379406
http://dx.doi.org/10.1016/j.lrr.2014.05.003
_version_ 1782342242045788160
author Bjørn, M.E.
de Stricker, K.
Kjær, L.
Ellemann, K.
Hasselbalch, H.C.
author_facet Bjørn, M.E.
de Stricker, K.
Kjær, L.
Ellemann, K.
Hasselbalch, H.C.
author_sort Bjørn, M.E.
collection PubMed
description We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.
format Online
Article
Text
id pubmed-4216335
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-42163352014-11-06 Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera Bjørn, M.E. de Stricker, K. Kjær, L. Ellemann, K. Hasselbalch, H.C. Leuk Res Rep Case Report We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy. Elsevier 2014-08-01 /pmc/articles/PMC4216335/ /pubmed/25379406 http://dx.doi.org/10.1016/j.lrr.2014.05.003 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Case Report
Bjørn, M.E.
de Stricker, K.
Kjær, L.
Ellemann, K.
Hasselbalch, H.C.
Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
title Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
title_full Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
title_fullStr Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
title_full_unstemmed Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
title_short Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
title_sort combination therapy with interferon and jak1-2 inhibitor is feasible: proof of concept with rapid reduction in jak2v617f-allele burden in polycythemia vera
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216335/
https://www.ncbi.nlm.nih.gov/pubmed/25379406
http://dx.doi.org/10.1016/j.lrr.2014.05.003
work_keys_str_mv AT bjørnme combinationtherapywithinterferonandjak12inhibitorisfeasibleproofofconceptwithrapidreductioninjak2v617falleleburdeninpolycythemiavera
AT destrickerk combinationtherapywithinterferonandjak12inhibitorisfeasibleproofofconceptwithrapidreductioninjak2v617falleleburdeninpolycythemiavera
AT kjærl combinationtherapywithinterferonandjak12inhibitorisfeasibleproofofconceptwithrapidreductioninjak2v617falleleburdeninpolycythemiavera
AT ellemannk combinationtherapywithinterferonandjak12inhibitorisfeasibleproofofconceptwithrapidreductioninjak2v617falleleburdeninpolycythemiavera
AT hasselbalchhc combinationtherapywithinterferonandjak12inhibitorisfeasibleproofofconceptwithrapidreductioninjak2v617falleleburdeninpolycythemiavera

Ejemplares similares